two blows against allergan

Bouchard did not seem convinced with the reasoning provided by Allergan's lawyers. He said, “It’s pretty apparent to me that Allergan may not want to have a special meeting at all.” This statement serves yet another blow to Allergan, which is still recovering from last week's legal proceedings in California. US District Judge David Carter denied Allergan’s request last week for an expediting hearing on its insider-trading lawsuit filed against Valeant

 

The deal will be completed by end of year without a doubt

 

This assumes that Allergan shareholders see value in Valeant stock. Maybe...maybe not.

 

Who cares